公开(公告)号：US20220257660A1

公开(公告)日：2022-08-18

申请号：US17732190

申请日：2022-04-28

申请人： NantCell, Inc. ,  NantBio, Inc. ,  ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Hans G. Klingemann

IPC分类号： A61K35/17 ,  A61P35/00 ,  C12N5/0783 ,  C07K14/54

摘要： Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

公开(公告)号：US20220168349A1

公开(公告)日：2022-06-02

申请号：US17438386

申请日：2020-02-27

申请人： NANTCELL, INC. ,  NantBio, Inc. ,  NantKwest, Inc.

发明人： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Hans G. Klingemann

IPC分类号： A61K35/17 ,  C07K14/54 ,  C12N5/0783 ,  A61P35/00

摘要： Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

公开(公告)号：US11573230B2

公开(公告)日：2023-02-07

申请号：US16964325

申请日：2019-01-25

申请人： NANTCELL, INC. ,  NANTBIO, INC.

发明人： Adrian E. Rice ,  Kayvan Niazi ,  Frank R. Jones

IPC分类号： C12Q1/70 ,  G01N33/569 ,  A61K39/00 ,  C12N15/86

摘要： Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.

公开(公告)号：US20240075129A1

公开(公告)日：2024-03-07

申请号：US18488629

申请日：2023-10-17

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC分类号： A61K39/215 ,  C12N15/861

CPC分类号： A61K39/215 ,  C12N15/861 ,  A61P31/14

摘要： Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US20240299521A1

公开(公告)日：2024-09-12

申请号：US18664120

申请日：2024-05-14

申请人： NantBio, Inc.

发明人： Kayvan Niazi ,  Raymond Wong ,  Peter Sieling ,  Philip T. Liu

IPC分类号： A61K39/108 ,  A61K9/00 ,  A61K39/00 ,  C12N15/861

CPC分类号： A61K39/0258 ,  A61K39/0002 ,  C12N15/861 ,  A61K9/0019 ,  A61K2039/605 ,  C12N2770/16034

摘要： Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

公开(公告)号：US12016883B2

公开(公告)日：2024-06-25

申请号：US17033265

申请日：2020-09-25

申请人： NantBio, Inc.

发明人： Krsto Sbutega ,  Peter Sieling ,  Adam D. Lazar ,  Kayvan Niazi

IPC分类号： A61K35/17 ,  A61K45/00 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K45/05 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2818 ,  C12N5/0636 ,  C12N2501/20

摘要： Provided herein are methods of in-vitro primary T cell growth that enrich T cells in a blood sample, stimulate the T cells with anti-CD2, anti-CD3, and/or anti-CD28 and that expand the T cells with a cytokine. Also provided are methods of treating a tumor in a patient using the expanded T cells.

公开(公告)号：US20240197786A1

公开(公告)日：2024-06-20

申请号：US18415101

申请日：2024-01-17

申请人： NantBio, Inc.

发明人： Patrick Soon-Shiong ,  Francesco Curcio ,  Kayvan Niazi

IPC分类号： A61K35/28 ,  A61K45/06

CPC分类号： A61K35/28 ,  A61K45/06

摘要： Compositions and methods are presented that include exosomes from stem cells and/or tumor cells that were previously exposed to an inflammatory stimulus. Advantageously, such exosomes exhibit anti-inflammatory and analgesic effect when administered to an individual. Therefore, a preferred use of such exosomes will reduce the need for opioid analgesics, and reduce pain and inflammation.

公开(公告)号：US20240084011A1

公开(公告)日：2024-03-14

申请号：US18001566

申请日：2021-06-09

申请人： NantBio, Inc.

发明人： Clifford Anders Olson ,  Shiho Tanaka ,  Kayvan Niazi ,  Melanie Hermreck ,  Thomas H. King ,  Zhimin Guo

IPC分类号： C07K16/28 ,  A61K49/00 ,  A61P35/00

CPC分类号： C07K16/2818 ,  A61K49/0002 ,  A61P35/00 ,  C07K2317/35 ,  C07K2317/622

摘要： Compositions and methods are presented in which selected polypeptide compounds bind to CTLA-4. Most typically, binding is mediated by selected VH and/or VL domains, and preferred compounds are prepared as scFv, IgG, or CAR.

公开(公告)号：US20240018274A1

公开(公告)日：2024-01-18

申请号：US18339155

申请日：2023-06-21

申请人： NantBio, Inc.

发明人： Kayvan Niazi ,  Wael Tadros ,  Annie Shin

IPC分类号： C07K19/00 ,  C07K14/575 ,  C07K14/725 ,  C12N15/10 ,  C12N15/86

CPC分类号： C07K19/00 ,  C07K14/575 ,  C07K14/7051 ,  C12N15/102 ,  C12N15/86 ,  C07K2319/912 ,  C12N2710/10111

摘要： Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.

公开(公告)号：US11034951B2

公开(公告)日：2021-06-15

申请号：US16264304

申请日：2019-01-31

申请人： NantBio, Inc.

发明人： Clifford Anders Olson ,  Kayvan Niazi

IPC分类号： C40B50/06 ,  C12N15/10 ,  C40B40/10 ,  C12N15/86 ,  C12N5/09 ,  C40B40/02 ,  C12N15/85

摘要： Compositions, methods and uses of a recombinant virus and/or recombinant viral vector encoding a distinct antibody or antibody fragment generated from high-diversity nucleic acid library are presented. Preferably, the recombinant virus is genetically modified, low immunogenic virus, for example, an E2b-deleted adenovirus. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.